Cheong Wing L, Mohan Devi, Warren Narelle, Reidpath Daniel D
School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia.
Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS), Monash University Malaysia, Bandar Sunway, Malaysia.
Front Neurol. 2018 Jun 8;9:432. doi: 10.3389/fneur.2018.00432. eCollection 2018.
Multiple sclerosis is thought to be relatively uncommon in the Asia Pacific region with prevalence estimated between 0 and 20 per 100,000. There is reason to doubt these estimates due to the lack of data from many countries and the growing evidence of variability in prevalence across small geographic areas. This study was conducted to systematically review the population prevalence, incidence, mortality and disability progression estimates of MS within the Asia Pacific region. The systematic review was conducted on articles from 1985 till 31st July 2017 within the PubMed/MEDLINE, EMBASE, SCOPUS, and The Cochrane Library databases. The review included articles that were population-based studies conducted on patients with MS in the Asia Pacific region that reported either incidence, prevalence, mortality, or disease progression. Hospital-based studies and non-research articles were excluded to ensure that only information representative of the population was included for analysis. Data appraisal and extraction was done by independent reviewers. This review was registered with PROSPERO (ID: CRD42017082760). Of the 2,757 articles found, 16 studies were included. Information on 6 (18.75%) of 32 Asia Pacific countries was found, with data representing 8% of the total population. Prevalence estimates were available for 6 countries while estimates for incidence (3 countries), mortality (4 countries), and disease progression (2 countries) were limited. The lack of epidemiological data available in the Asia Pacific region creates a blind spot in the surveillance of MS which obscures the true burden of MS, causing patients to struggle to receive the resources and funding that they need.
多发性硬化症在亚太地区被认为相对不常见，估计患病率为每10万人中有0至20例。由于许多国家缺乏数据，且越来越多的证据表明小地理区域内患病率存在差异，因此有理由怀疑这些估计。本研究旨在系统回顾亚太地区多发性硬化症的人群患病率、发病率、死亡率和残疾进展估计。对1985年至2017年7月31日期间发表在PubMed/MEDLINE、EMBASE、SCOPUS和Cochrane图书馆数据库中的文章进行了系统回顾。该回顾纳入了对亚太地区多发性硬化症患者进行的基于人群的研究，这些研究报告了发病率、患病率、死亡率或疾病进展情况。排除了基于医院的研究和非研究文章，以确保仅纳入代表人群的信息进行分析。数据评估和提取由独立评审员完成。本回顾已在PROSPERO注册（ID：CRD42017082760）。在找到的2757篇文章中，纳入了16项研究。在32个亚太国家中发现了6个国家（18.75%）的信息，数据代表了总人口的8%。有6个国家提供了患病率估计，而发病率（3个国家）、死亡率（4个国家）和疾病进展（2个国家）的估计有限。亚太地区缺乏可用的流行病学数据，在多发性硬化症监测方面形成了一个盲点，掩盖了多发性硬化症的真实负担，导致患者难以获得所需的资源和资金。
